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Summary Bone is innervated by sympathetic and sensory neurons, which play important roles
in bone remodeling. Direct neuro-osteogenic cross-talk has been demonstrated using an in vitro
co-culture model comprising osteoblastic or osteoclastic cells, and neurite-spouting mouse
superior cervical ganglia, suggesting that these cells are directly regulated by sympathetic
neurons. The increase in sympathetic nervous activity causes bone loss through increased bone
resorption and decreased bone formation, associated with b2-adrenergic activity toward both
osteoblastic and osteoclastic cells. The increased bone resorption is based on the stimulation of
both osteoclastogenesis and osteoclastic activity. These studies suggest b-blockers to be effec-
tive against osteoporosis, in which case there is increased sympathetic activity. Epidemiological
studies have demonstrated high blood pressure to be associated with increased bone loss and b-
blockers to be potential candidates for drugs to treat osteoporosis and fractures. In animal
experiments, a lower dose of b-blocker also improved bone mass and biomechanical fragility in a
hypertensive model. Although the interplay between sympathetic and sensory neurons is poorly
understood, interestingly, sensory denervated rats have been demonstrated to show similar bone
metabolism to rats with hyperactivity of sympathetic tone. This review summarized both in vitro
and in vivo evidence implicating sympathetic neuronal activity in bone resorption.
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Neural regulation of the bone metabolism mediated by
osteoblastic and osteoclastic cells has been demonstrated
[1—7]. Previous studies showed that human osteoblastic and
osteoclastic cells not only possess adrenergic receptors (ARs)
and neuropeptide receptors but also constitutively express
axon guidance molecules for growing nerve fibers [8,9].
These findings together with the immunohistochemical evi-
dence that mammalian bones are widely innervated by sym-
pathetic and sensory nerves suggest that the extension of the
axons of sympathetic and peripheral sensory nerves to osteo-
blastic and osteoclastic cells is required for the dynamic
neural regulation of local bone metabolism. Direct nerve-
osteoblastic cell communication was revealed using an in
vitro co-culture model comprising osteoblastic cells, and
neurite-spouting superior cervical ganglia [10,11]. Recent
bulk experimental studies showed that the sympathetic ner-
vous system was involved in increasing bone resorption and
decreasing bone formation, and that b-AR antagonists were
effective against osteoporosis attributed to increased sym-
pathetic nervous activity. Then, although neuropeptides are
known to have significant osteotropic effects on bone meta-
bolism [12,13], neuropeptide Y (NPY) and calcitonin gene-
related peptide (CGRP) have been a focus of our research,
because of their modifying effect on osteoclastogenesis eli-
cited by adrenergic stimulation [14,15].
The present article reviews our current understanding of the
neuro-osteogenic network and sympathetic effects on bone
resorption based on a variety of studies in vivo and in vitro. It
also covers the physiological modification of sympathetic
effects on bone resorption and discusses the role of neuropep-
tides in the modulation of adrenergic bone resorption.
2. Nerve-bone cell interplay
2.1. Adrenergic receptors and neuropeptide
receptors
Histochemical approaches have revealed the presence of
vasoactive intestinal peptide (VIP), CGRP, substance P (SP),
NPY, and noradrenaline (NA) in osseal nerve fibers [16,17].
Pharmacological evidence also shows that both osteoblas-
tic cells and osteoclastic cells possess receptors for neu-
ropeptides and NA. These observations suggest that the
expression of these receptors physiologically regulates
bone cell activities. In 1997, we demonstrated that a1B-AR, a2B-AR, b2-AR, CGRP-R, NPY-R, and VIP-1R, but not
a1A-AR, a1D-AR, a2C-AR, b1-AR, b3-AR, SP-R, VIP-2R, and
pituitary adenylate cyclase-activating polypeptide
(PACAP)-R, were expressed in human periosteum-derived
osteoblastic cells (SaM-1) and human osteosarcoma-
derived cells (SaOS-2, HOS, MG-63) by the use of the
reverse transcription-polymerase  chain reaction (RT-PCR)
[8]. The expression of these receptors seems to be a
common feature of osteoblastic cells, but the magnitude
of expression was not dependent upon the relative state of
commitment of the osteoblastic cells to the osteoblast
lineage (Table 1). In the osteoclastic cells, a1B-AR, a2B-
AR, b2-AR, CGRP-R, SP-R and VIP-1R were expressed (Table
1). SaM-1 and human osteoclastic cells, generated from
bone marrow, expressed several phenotypes typical of
mature cells. Recently, the expression of ARs was also
detected by immunofluorescence microscopy and Western
blotting in human osteoblasts [18]. From these results, it
was revealed that human osteoblastic as well as ost
eoclastic cells are equipped with ARs and neuropeptide
receptors.
2.2. Diffusible axon guidance molecules
During the development of the nervous system, neuronal
growth cones traverse appropriate pathways to find their
targets. Extending axons in the developing nervous system
are guided to their targets through the coordinated actions of
attractive and repulsive guidance cues. These mechanisms are
mediated by many different families of guidance molecules
secreted by target cells such as neurotrophins (chemoattrac-
tants), semaphorin-III (a chemorepellent), and netrins (che-
moattractants and chemorepellents) [19]. In order to
determine the ability of osteoblastic and osteoclastic cells
to produce these diffusible axon guidance molecules, the
steady-state expression of neurotrophins (NGF, nerve growth
factor; BDNF, brain derived neurotrophic factor; NT-3, neuro-
trophin-3), semaphorin-III (Sema-III), netrins (NTN1, netrin-1;
NTN2L, netrin-2-like protein) has been analyzed in SaM-1,
SaOS-2, HOS, MG-63, and human osteoclastic cells by RT-
PCR, ELISA, and Western blot analysis [9]. SaM-1 cells
expressed NGF, BDNF, NT-3, Sema-III, NTN1, and NTN2L after
reaching confluence (Table 1). Their expression was also
detected in osteosarcoma-derived cells, though the
magnitude of expression was different. Human osteoclastic
cells expressed NGF, BDNF, Sema-III, and NTN1, but not
NTN2L. Thus, both osteoblastic and osteoclastic cells also
Table 1 Expression of mRNAs for adrenergic receptors, neuropeptide receptors, and axon guidance molecules in human
osteoblastic and osteoclastic cells.
SaM-1 SaOS-2 HOS MG-63 Osteoclast
Adrenergic receptors a1A-R (60)     
a1B-R (30) + +++ +++ ++ ++
a1D-R (60)     
a2A-R (60)  +  + 
a2B-R (60) +  +  ++
a2C-R (60)     
b1-R (30)     
b2-R (30) ++ ++ ++ ++ ++
b3-R (30)     
Neuropeptide receptors CGRP-R (45) + + + +++ ++
NPY-R (60) ++ + +  
SP-R (60)     ++
VIP-1R (35) + +++ ++ + ++
VIP-2R (35)     
PACAP-R (35)     
Axon guidance molecules NGF (30) ++ +++  + +
BDNF (30) ++ ++ +++ + +
NT-3 (30) ++ +++  ++ 
Sema-III (35) + ++ ++ ++ +++
NTN1 (32) + ++ +++ ++ +
NTN2L (32) + +++ +++ ++ 
() no, (+) faint, (++) medium, (+++) strong expression. Number: cycles for PCR amplification.
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known to function as chemoattractants and/or chemorepel-
lents for growing nerve fibers. These findings may suggest that
the extension of axons of sympathetic and peripheral sensory
neurons to osteoblastic and osteoclastic cells is required for
the dynamic neural regulation of local bone metabolism.
Therefore, it has been proposed that signaling molecules in
the nervous system may participate in the control of local bone
metabolism and that, consequently, a neuro-osteogenic net-
work may exist, one similar to previously proposed neuro-
immune and neuro-immune-endocrine interacting systems
[20—22].
2.3. Nerve-bone cell communication
Takeda et al. [2] demonstrated electron microscopically the
presence of peripheral nerve axons coursing through the
marrow adjacent to osteoblasts in bone tissue, in which case
actual membrane-membrane contacts were formed
between nerve and osteoblastic cells. However, whether
the activation of both osteoblastic and osteoclastic cells
occurs as a direct response to neuronal activation or requires
an intermediary cell is unclear. In 2007, direct nerve-osteo-
blastic cell communication was elucidated using an in vitro
co-culture model comprising mouse osteoblastic cells,
MC3T3-E1 cells, and neurite-spouting mouse superior cervi-
cal ganglia (Fig. 1) [10]. Following loading with the calcium
fluorophore Fluo-3, neurite-osteoblastic cell units were
examined by confocal laser scanning microscope. Addition
of scorpion venom (SV) elicited neurite activation (i.e., Ca2+
mobilization) and, after a lag period, osteoblastic Ca2+
mobilization. SV had no direct effect on the MC3T3-E1 cellsin the absence of neurites. Addition of an a1-AR antagonist,
prazosin, concentration-dependently prevented the osteo-
blastic activation that resulted as a consequence of neural
activation by SV. Thus, our recent findings demonstrate that
MC3T3-E1 cell activation, as judged by Ca2+ mobilization,
can be a direct consequence of contact with a specific
activated nerve fiber. This evidence obtained in vitro shows
that nerve-osteoblastic cell cross-talk can occur in the
absence of an intermediary transducing cell, and that NA
is an important mediator of this communication. A similar
technique also demonstrated nerve-osteoclastic cell cross-
talk [11].
Although, in the co-culture experiment, both osteoblas-
tic and osteoclastic activation was observed via a1-AR as a
direct response to neuronal activation, there are very few
reports of a physiological role for a-AR. In MC3T3-E1 cells,
a1-AR stimulation increased cell proliferation, alkaline
phosphatase activity, and type III Pi transporter activity
[23,24], and increased RANKL expression via protein kinase
C and extracellular signal-regulated kinase pathways [25].
Recently, using whole-cell patch clamp recordings, we also
found that a1B-adrenergic stimulation suppressed Cs-sensi-
tive and tetraethylammonium-insensitive potassium chan-
nels in SaM-1 cells [26]. Since potassium channel activity is
known to regulate membrane potential and cell prolifera-
tive capacity in various cells [27—30], a1-AR stimulation may
facilitate cell proliferation via a1B-AR through the regula-
tion of potassium channels in human osteoblasts. Anyway,
several in vivo and in vitro studies have demonstrated
sympathomimetic effects on bone formation and resorption
via osteoblastic and osteoclastic cells equipped with a- and
b-ARs.
Figure 1 Nerve-induced osteoblastic or osteoclastic cell activation. (A) Representative differential interference contrast (DIC)
images of the SCG-osteoblast (a) and the SCG-osteoclast (b) co-cultures. (B) Pharmacological analysis of the functional interaction
between neurons and osteoblastic or osteoclastic cells in a co-culture experiment. Scorpion venom, a neurotoxin, opens neural Na+
channels to cause depolarization and increase [Ca2+]i. Then, it stimulates neurons to release neurotransmitters from the synaptic
vesicles of nerve endings. If there is functional cellular interaction, the neurotransmitters released from neurons act on the receptors
of osteoblastic or osteoclastic cells to increase [Ca2+]i within them as well.
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3.1. Effect of adrenergic agonists on
osteoclastogenesis
Bone marrow culture techniques have been successfully
employed to study the development of osteoclasts from their
precursor cells. Such cultures provide an appropriate system
to investigate osteotrophic hormones, cytokines, and other
bone-active factors that may be involved in the generation of
osteoclasts. In this culture system, receptor activator of NF-
kB ligand (RANKL) and osteoprotegerin (OPG) were reported
to play an essential role in osteoclastic differentiation. The
expression of both proteins was reported to be regulated by
several osteotrophic factors including 1a,25-dihydroxyvita-
min D3 (1a,25(OH)2D3), interleukin (IL)-1a, IL-11, prostaglan-
din (PG)E2, transforming growth factor-b1, and parathyroid
hormone [31—35]. In 2001, adrenaline and isoprenaline, b-AR
agonists, have been also demonstrated to modulate osteo-
clastogenesis. The involvement of RANKL and/or OPG in
adrenaline-induced bone resorption was shown by determin-
ing the effect of adrenaline on the mRNA expression of RANKL
and OPG in MC3T3-E1 cells and the formation of tartrate-
resistant acid phosphatase (TRAP)-positive multinuclear cells
(MNCs) in mouse bone marrow cultures, thus providing a
better understanding of the bone resorption induced by
the sympathetic system [36]. Use of the RT-PCR procedure
revealed that the expression of RANKL and OPG mRNAs in
osteoblastic cells was regulated by adrenergic stimulation
[36]. The expression of RANKL and OPG elicited by adrenaline
appeared to be mediated by b-adrenergic and a-adrenergic
stimulation, respectively. Treatment of mouse bone marrowcells with adrenaline or isoprenaline generated TRAP-posi-
tive MNCs capable of excavating resorptive pits on dentine
slices, and caused an increase in RANKL and a decrease in
OPG production by the marrow cells [5,15,36]. The osteoclast
formation was significantly inhibited by OPG, suggesting the
involvement of the RANKL-RANK system. Since the osteoclas-
togenesis in mouse bone marrow cells was not stimulated by
an a-AR agonist, it may be regulated by the balance between
RANKL and OPG production in osteoblasts/stromal cells.
Fig. 2 schematically shows a possible mechanism for the
adrenergic stimulation of osteoclastogenesis.
3.2. Effect of adrenergic agonists on osteoclastic
activity
In neonatal mouse calvariae, AR agonists stimulated cyclic
AMP (cAMP) synthesis and bone resorption in the presence of
a phosphodiesterase inhibitor and an antioxidant [37]. The
stimulation of cAMP synthesis by b-AR agonists was inhibited
by propranolol in a bone organ culture [38]. The b-adrenergic
stimulation of bone resorption might be mediated by directly
activated osteoclasts and osteoclastogenesis enhanced by
osteotrophic factors released from osteoblasts. In human
osteoclastic cells constitutively expressing a1B-, a2B-, and
b2-ARs, b-AR agonists upregulated the expression of char-
acteristic markers of the mature osteoclast, such as integrin,
carbonic anhydrase II, and cathepsin K; increased osteoclas-
tic bone-resorbing activity; and clearly caused actin ring
formation [39]. These findings were not obtained on treat-
ment with a-AR agonists, and suggest that b-AR agonists
directly stimulate bone-resorbing activity in mature osteo-
clasts. In a clonal cell line of human osteoclast precursors
Figure 2 Schematic diagram of adrenergic action on osteoclastogenesis and osteoclastic avtivity. Both osteoblasts and osteoclasts
constitutively express a1B-, a2B- and b2-ARs. Stimulation of b2-ARs increases osteoclast formation and the expression of RANKL, IL-6, IL-
11, and PGE2 in bone marrow or clonal osteoblastic cells. The increase in osteoclasts is inhibited by OPG treatment, suggesting the
involvement of the RANKL-RANK system in osteoclastogenesis caused by stimulating b2-ARs. The expression of RANKL and OPG in MC3T3-
E1 cells is increased by stimulating b2-ARs and a-ARs, respectively. In human osteoclasts, stimulation of b-ARs activates osteoclastic
activity. Thus, increased sympathetic activity stimulates osteoclast formation as well as osteoclastic activity through b2-ARs.
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act as inducers of osteoclastic maturation in vitro and as
stimulators of osteoclastic activity via binding to b2-ARs [40].
As osteoclastogenesis-enhancing osteotrophic factors pro-
duced by b-adrenergic stimulation, IL-6, IL-11, and PGE2
were detected in human and mouse osteoblastic cells
[36,41]. The coexpression of IL-6 and IL-11 induced by the
activation of b-ARs, which appears to be a common feature of
osteoblastic cells, has been shown to be mediated via a
common signaling pathway involving the protein kinase A
and p38 mitogen-activated protein kinase systems, leading to
the transcriptional activation of activator protein-1 in human
osteoblastic cells. Thus, AR agonists cause the catabolic
effect on bone metabolism via the b-adrenergic system.
Nevertheless, Elefteriou et al. reported that isoprenaline
did not stimulate cAMP production in bone marrow macro-
phages treated with RANKL and macrophage colony-stimu-
lating factor [5], indicating the b-agonist to have an indirect
rather than direct effect on mature osteoclasts. Further
research may be necessary to gain a better understanding
of how b-agonists act on mature osteoclasts.
3.3. Sympathetic regulation of bone resorption
in vivo
There are several lines of evidence that the sympathetic
nervous system modulates bone resorption in vivo. Surgical
removal of the superior cervical ganglion increased bone
resorption [42], as did chemical treatment with guanethidine
in newborn rats [43]. However, in adult rats treated with
guanethidine, bone resorption was reduced [44]. The reduc-
tion in bone resorption was assumed to reflect the acuteeffects of the sympathectomy. By using a compartmentaliza-
tion procedure, the resorption surface in the osteogenic
compartment was found to be significantly reduced in the
guanethidine-treated rats, accompanied by a fall in the
number of osteoclasts and impaired access to the bone sur-
face. The effect on resorption that the sympathectomy had
by inhibiting preosteoclastic differentiation and disturbing
osteoclastic activation suggests that depletion of sympa-
thetic mediators could disturb osteogenic cell-mediated
osteoclastic differentiation. In addition, sympathectomy-
induced depletion of NA may be another possible mechanism
for the reduction in bone resorption. Such a notion is sup-
ported by several significant findings including the stimula-
tion of bone resorption in a tissue culture system [37], an
increase in preosteoclastic cell activity [40], and stimulation
of the synthesis of osteoclast-like cell formation-stimulating
factors in osteoblastic cells by b-adrenergic stimulation
[36,41].
The intracerebroventricular (i.c.v.) injection of lipopoly-
saccharide (LPS), an inflammatory stimulus in the brain, was
demonstrated to increase output from the peripheral sym-
pathetic nervous system. To prove the physiological role of
the sympathetic nervous system in bone metabolism in vivo,
RT-PCR was performed to examine the effect of an i.c.v.
injection of LPS on cyclooxygenase-2 and IL-6 mRNA expres-
sion in mouse calvaria [45,46]. The expression of both mRNA
was increased by the injection. The increases were inhibited
by treatment with the neurotoxin 6-hydroxydopamine (6-
OHDA) or b-AR antagonists. Similarly, restraint stress induced
the expression of IL-6 mRNA in mouse calvaria [46]. This
induction was not influenced by 6-OHDA, but was inhibited by
propranolol. In addition, the treatment of calvaria with
isoprenaline or NA increased PGE2 and IL-6 synthesis in the
Figure 3 Schematic diagram of bone metabolism modulated by the sympathetic nervous system. Central activation of the peripheral
sympathetic nervous system caused by the intracerebroventricular (i.c.v.) injection of lipopolysaccharide (LPS) or leptin and by
restraint stress alters bone formation and bone resorption. Centrally mediated activation of the nervous system is associated with
increased catecholamine levels. Leptin-induced sympathetic activation has been reported to decrease bone formation via osteoblastic
activity. Conversely, both LPS- and stress-induced activation increase the synthesis of osteoclastogenetic factors such as IL-6, and
PGE2, which leads to bone resorption. Chronic stimulation of b-AR also induces bone loss due to increased osteoclastic activity rather
than inhibition of bone formation.
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gene expression caused by a restraint stress or i.c.v. injection
of LPS was mediated by the activation of sympathetic nerve
fibers and b-ARs in mouse calvaria and suggest that in vivo
activation of the sympathetic nervous system modulates bone
resorption. Such results are strongly supported by the findings
of Karsenty’s group [5], who reported that b2-AR-deficient
(Adrb2/) mice had a more severe high bone mass phenotype
than wild-type mice receiving b-AR antagonists and that long-
term leptin i.c.v. infusion did not reduce bone mass in Adrb2/
 mice. Furthermore, they showed that the sympathetic
nervous system favors bone resorption by increasing the
expression of RANKL and that isoprenaline enhanced the gen-
eration of osteoclasts when wild-type, but not Adrb2/,
osteoblasts were co-cultured with wild-type bone marrow
macrophages. Moreover, using osmotic minipumps implanted
into the subcutaneous tissue in the back, we recently demon-
strated that chronic stimulation of b-AR with low-dose iso-
prenaline treatment induces bone loss due to increased
osteoclastic activity rather than inhibition of bone formation
[47]. Thus, these in vivo experiments modulating peripheral
sympathetic nervous activity suggest that increased sympa-
thetic nervous activity leads to increase bone resorption
through b2-ARs. To integrate these recent findings, we have
presented a possible mechanism for the regulation of bone
metabolism via the sympathetic nervous system in Fig. 3.
3.4. Experimental and clinical evaluation of the
effects of b-AR antagonists (b-blockers) on bone
fracture risk
Both in vitro and in vivo experimental studies indicate b-
blockers to be effective against osteoporosis attributed toincreased sympathetic nervous activity. The use of b-block-
ers to inhibit bone resorption and/or to stimulate bone
formation could, therefore, be an important new approach
to treating osteoporosis. In population-based, case-control
studies involving adult women [48], adult men and young
women [49], the use of b-blockers, taken alone as well as in
combination with thiazide diuretics, was demonstrated to be
associated with a reduced risk of fractures. Thus, b-blockers
generally do cause a reduction in bone fracture risk and
higher bone mineral density. Another prospective study,
however, found no association between b-blocker use and
fracture risk in perimenopausal and older women [50—52].
Therefore, there is currently no convincing evidence support-
ing the hypothesis that pharmacological blockade of the b-
adrenergic system is beneficial to the human skeleton after
menopause. Although b-adrenergic stimulation can be pro-
posed as one of the causes of osteoporosis in experimental
studies, the clinical usefulness of b-blockers for fracture risk
must be analyzed in several patients with increased sympa-
thetic nervous activity. Specifically, it is important to find a
difference between users and nonusers with increased sym-
pathetic tone.
To evaluate the effectiveness of b-blockers for experi-
mental osteoporosis with hyperactivity of the peripheral
sympathetic nervous system, bone mass was analyzed in
the spontaneously hypertensive rat (SHR), a hypertensive
model with enhanced sympathetic nervous activity. The
SHR exhibited significantly decreased cancellous bone den-
sity as well as markedly increased blood pressure [53].
Specifically, bone density and strength in the lumbar spine
decreased. Histochemistry showed decreased bone forma-
tion, increased numbers of osteoclasts, decreased serum
levels of osteocalcin, a bone formation marker, and increased
TRAP 5b activity, a systemic bone resorption marker. These
Figure 4 Schematic diagram of the b-adrenergic regulation of
bone metabolism involved in bone fracture risk. Several experi-
mental studies suggested that b-AR antagonists decreased the
risk of bone fractures. Then, clinical studies showed the phar-
macological effectiveness of b-blockers in reducing bone-frac-
ture risk. Recently, in SHR showing osteoporosis as well as
hypertension, the effectiveness of b-blockers against bone loss
and bone fragility was confirmed. The reduced bone mass in SHR
with enhanced sympathetic nerve activity is caused by increased
bone resorption and decreased bone formation, as compared
with control rats (WKY). The reduced bone mass is accompanied
by bone fragility. The bone mass in SHR recovered to WKY’s level
when b2-AR was suppressed.
The neuro-osteogenic network 67changes were improved with a low dose of propranolol, which
has no effect on blood pressure [53]. The b-blocker timolol
and selective b2-blocker butoxamine, which have no mem-
brane-stabilizing effect, also improved the bone density.
Thus, in SHR with enhanced sympathetic nerve activity, bone
loss was improved by blocking b2-ARs with a low dose of
b-blockers (Fig. 4). These results are similar to the effects of
propranolol, as observed by Bonnet et al. [54] in ovariecto-
mized (OVX) rats. The results may be associated with
enhanced sympathetic activity in OVX rats.Figure 5 Schematic diagram of a working hypothesis for the po
Stimulation of sympathetic neurons as well as denervation of sensory 
decrease in bone formation. The strong resemblance between sen
sensory activity functionally interacts with the sympathetic activity
formation; white arrow: effects on osteoclastic bone resorption.4. Physiological modification of sympathetic
effect on bone resorption
4.1. Neuropeptides modifying adrenergic
osteoclastogenesis in vitro
In mammalian species, nerve fibers containing several neu-
ropeptides, such as NPY, CGRP, VIP, and SP, as well as NA, a
classical neurotransmitter, have been identified in the vici-
nity of bone tissue [55—58]. In accordance with the neuro-
osteogenic hypothesis, these neuropeptides can be released
from nerve endings and transmit physiological signals to
osteoblastic and osteoclastic cells present close by. Although
these neuropeptides produce significant osteotropic effects
on bone metabolism [12,13], NPY and CGRP have been
demonstrated to modulate osteoclastogenesis elicited by
adrenergic stimulation [14,15].
NPY is co-localized with NA in sympathetic nerve terminals
[59—62] and recognized as a co-transmitter with NA in
peripheral sympathetic nerve fibers. Studies have revealed
that NPY inhibits cAMP production in the target cell [63,64].
Indeed, NPY inhibited the stimulatory effect of NA on cAMP in
UMR-106-01 cells and isolated bone cells [65]. In addition,
NPY has been demonstrated to inhibit b-adrenergic- or
VIPergic-stimulated accumulation of cAMP in the pineal
gland, which is mediated through a pertussis toxin-sensitive
G protein. Recently, the effect of NPY on osteoclastogenesis
has been demonstrated in mouse bone marrow cell cultures
treated with isoprenaline [14]. The mouse bone marrow cells
constitutively expressed mRNAs for the NPY-Y1 receptor and
b2-AR. NPY inhibited the formation of osteoclast-like cells
induced by isoprenaline but not by 1a,25(OH)2D3 or soluble
RANKL; and suppressed the production of RANKL and cAMP
increased by isoprenaline but not by 1a,25(OH)2D3. NPY also
inhibited osteoclastogenesis induced by forskolin, an activa-
tor of adenylate cyclase; but not that induced by dibutyryl
cAMP, a cell-permeable cAMP analog that activates cAMP-ssible interaction between sympathetic and sensory neurons.
neurons causes bone loss via an increase in bone resorption and a
sory denervation and sympathetic hyperfunction, suggests that
 in bone metabolism. Black arrow: effects on osteoblastic bone
68 A. Togari et al.dependent protein kinases. These results demonstrate that
NPY inhibited isoprenaline-induced osteoclastogenesis by
blocking agonist-elicited increases in the production of cAMP
and RANKL in mouse bone marrow cells, suggesting an inter-
action between NPY and b-AR agonists in bone resorption.
The present results indicate NPY to be a specific inhibitor of
b2-AR agonist-induced osteoclastic formation. The physiolo-
gical relevance of this observation is that NPY substantially
co-existed with NA in the sympathetic nerve terminals to
control the b-adrenergic stimulation of NA released simul-
taneously; because similar effects of NPY had been observed
in the cells and tissues controlled by b-adrenergic regulation.
CGRP is a neuropeptide abundant in sensory neurons
innervating the skeleton and regulates bone integrity. CGRP
has been demonstrated to inhibit the bone-resorbing activity
of isolated osteoclasts [66,67], and calcium release in bone
tissue cultures [68,69]. It also significantly inhibited
1a,25(OH)2D3-induced osteoclastogenesis in macrophages
[70]. In bone marrow cell cultures, CGRP inhibited the for-
mation of osteoclasts caused by isoprenaline or soluble
RANKL but had no influence on RANKL or OPG production
by the bone marrow cells treated with isoprenaline, suggest-
ing that CGRP inhibited the osteoclastogenesis by interfering
with the action of RANKL produced by the isoprenaline-
treated bone marrow cells without affecting RANKL or OPG
production [15]. Thus, the b-AR agonist generated osteo-
clasts from mouse bone marrow cells via the RANKL-RANK
system. Also, CGRP significantly inhibited this RANKL-
mediated osteoclastogenesis by interfering with the action
of RANKL in bone marrow macrophages [71]. Although these
in vitro data suggest the physiological interaction of sympa-
thetic and sensory nerves in osteoclastogenesis in vivo, the
physiological significance remains to be established.
4.2. Relationship between the sympathetic and
sensory nervous systems
Substantial evidence has accumulated that sympathetic ner-
vous activity causes bone loss via an increase in bone resorp-
tion and a decrease in bone formation. Sympathetic
denervation is known to be associated with a significant
increase in the number of CGRP-immunoreactive sensory
nerve fibers [72]. b-AR blockers not only improve bone loss
in SHR with hyperactivity of the peripheral sympathetic tone
[53] but also increase the release of CGRP from sensory nerve
fibers in SHR [73]. Furthermore, like b-blocker, CGRP par-
tially inhibits bone loss in OVX rats [74]. These studies may
suggest physiological interaction between sympathetic and
sensory nerves in bone metabolism.
The effects of sensory denervation on bone metabolism
are usually examined in animals treated with capsaicin,
which destroys unmyelinated and small-diameter myelinated
sensory neurons via the activation of transient receptor
potential vanilloid 1 expressed by sensory neurons. There
are less SP-containing nerve fibers than CGRP-containing
nerve fibers [75], so the sensory nerve fibers ablated by
capsaicin are mainly CGRP-containing nerve fibers. Capsaicin
treatment caused the destruction of the skeletal structure in
adult rats [76,77]. In our experiment [77], it reduced trabe-
cular bone volume due to increased trabecular separation in
the proximal tibia and the modification of mechanicalproperties such as strength, ductility, and toughness toward
increasing bone fragility in the trunk of the sixth lumber
vertebrae. Bone histomorphometry showed an increase in
osteoclast numbers and surface area. Capsaicin significantly
increased the level of TRAP 5b in plasma but had no influence
on the plasma osteocalcin concentration suggesting that
capsaicin-induced sensory nerve denervation increased bone
resoption but had no influence on bone formation. These
results show that sensory nerve innervation contributes to
the maintenance of trabecular bone mass and its mechanical
properties by inhibiting bone resorption.
Thus, there is a strong resemblance between sensory
denervation and sympathetic activation in bone metabolism,
suggesting that a sensory activity functionally interacts with
the sympathetic activity in osteoclastic formation. Fig. 5
schematically represents a working hypothesis for the pos-
sible interaction of sympathetic and sensory neurons.
5. Concluding remarks
An in vitro co-culture experiment demonstrated that the
responses to osteoblastic and osteoclastic cells produced by
neural stimulation were inhibited by AR antagonists, suggest-
ing that synaptic transmission occurs from nerve terminals to
these cells. Specifically, the peripheral nerve may be func-
tionally and directly connected to the osteoblastic and osteo-
clastic cells for regulating bone metabolism in vivo. If
osteoblastic activation is judged by cAMP, instead of the
Ca2+ used in our study, it would be possible to analyze the
molecular mechanism behind the communication mediated by
NA acting through b-ARs. There is currently great interest in
comparing the cellular interaction with other cellular inter-
actions, and in elucidating the physiological regulation of NA
secretion in neuro-osteogenic synapses. Thus, the in vitro co-
culture model is useful for studying the molecular mechanism
responsible for the neuro-osteogenic cross-talk. In SHR with
hyperactivity of the sympathetic nervous system, bone mass
and biomechanical fragility were markedly reduced by
increased bone resorption and decreased bone formation,
and improved by the b-blocker propranolol at lower doses
than those required to improve hypertension. Hypertension is
often accompanied by enhanced sympathetic nerve activity
and reduced bone mass. Comprehensive investigation may be
necessary to understand the mutual relationship among cal-
cium metabolism, bone metabolism, hypertension, and sym-
pathetic nerve activity. Notably, sympathetic regulation of
bone metabolism may be modified by sensory nervous activity,
as described in this article. Although there is currently great
interest in physiological modifications to signal transduction
and the synaptic integrity of sympathetic and sensory neurons,
further studies should clarify the mechanisms responsible for
these modifications in peripheral nervous systems and give
further insight into the neural regulation in bone metabolism.
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